Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10)

详细信息	查看全文 | 推荐本文 |

• 作者：Michael Perrotti ; Todd Doyle ; Parvesh Kumar ; Daryl McLeod ; William Badger ; Susan Prater ; Michael Moran ; Stuart Rosenberg ; Cora Bonatsos ; Carrie Kreitner ; Ralf Kiehl ; Theodore Chang ; Michael Kolodziej
• 关键词：Prostate cancer ; Docetaxel ; Radiosensitization
• 刊名：Urologic Oncology ; Seminars and Original Investigations
• 出版年：2008
• 期刊代码：266_10781439
• 类别：med
• 出版时间：May-June 2008
• 卷：26
• 期：3
• 页码：276-280
• 文件大小：91 K

摘要

A Phase I/II trial was conducted to assess the radiosensitizer docetaxel administered weekly (20 mg/m²) with concurrent intensity modulated radiation therapy (72 Gy at 1.8 Gy/fraction) in high risk prostate cancer.